Gyre Therapeutics (GYRE) Non-Current Receivables: 2023-2024
Historic Non-Current Receivables for Gyre Therapeutics (GYRE) over the last 2 years, with Dec 2024 value amounting to $5.0 million.
- Gyre Therapeutics' Non-Current Receivables rose 5.89% to $5.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.0 million, marking a year-over-year increase of 5.89%. This contributed to the annual value of $5.0 million for FY2024, which is 5.89% up from last year.
- As of Q4 2024, Gyre Therapeutics' Non-Current Receivables stood at $5.0 million, which was up 2.04% from $4.9 million recorded in Q3 2024.
- Over the past 5 years, Gyre Therapeutics' Non-Current Receivables peaked at $5.0 million during Q4 2024, and registered a low of $4.5 million during Q1 2023.
- In the last 2 years, Gyre Therapeutics' Non-Current Receivables had a median value of $4.8 million in 2023 and averaged $4.8 million.
- Data for Gyre Therapeutics' Non-Current Receivables shows a peak YoY rose of 5.89% (in 2024) over the last 5 years.
- Over the past 2 years, Gyre Therapeutics' Non-Current Receivables (Quarterly) stood at $4.7 million in 2023, then climbed by 5.89% to $5.0 million in 2024.
- Its last three reported values are $5.0 million in Q4 2024, $4.9 million for Q3 2024, and $4.8 million during Q2 2024.